Kiran Kakarala

Kiran Kakarala

Auto-generated profile, based on publicly available information

Kiran Kakarala

Department of Otolaryngology – Head and Neck Surgery University of Kansas Medical Center Kansas City Kansas USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
PDPeter Dziegielewski
Peter Dziegielewski
TTTheodoros N. Teknos
Theodoros N. Teknos
KDKasim Durmus
Kasim Durmus
MOMatthew Old
Matthew Old
AAAmit Agrawal
Amit Agrawal
EOEnver Ozer
Enver Ozer
Oropharyngeal squamous cell carcinoma (OPSCC) was historically treated with primary open surgery. Cure rates were low; complication rates were high; and patient health-related quality of life (HRQOL) decreased. In an effort to at least minimize morbidity, a quest for organ preservation protocols was undertaken,1-3 and treatment paradigms shifted toward primary external-beam radiation therapy (XRT) or chemoradiation therapy (CRT). Unfortunately, these protocols failed to provide desired solutions because they were often associated with significant acute and chronic toxic effects.4-6 The result was impaired upper aerodigestive tract function and suboptimal HRQOL.7,8 Therefore, head and neck surgeons are still seeking the ultimate balance between cancer cure, functional outcomes, minimal morbidity, and HRQOL.

1 February 2018 in Oral Oncology
Verified
Journal Article
Closed access
KKKiran Kakarala
Kiran Kakarala
YSYelizaveta Shnayder
Yelizaveta Shnayder
TTTerance T. Tsue
Terance T. Tsue
DGDouglas A. Girod
Douglas A. Girod

21 August 2012 in Head & Neck
Verified
Journal Article
Closed access
PDF file
EOEnver Ozer
Enver Ozer
BABianca Alvarez
Bianca Alvarez
KKKiran Kakarala
Kiran Kakarala
KDKasim Durmus
Kasim Durmus
TTTheodoros N. Teknos
Theodoros N. Teknos
RCRicardo L. Carrau
Ricardo L. Carrau

1 December 2015 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
Dhruv KumarDhruv Kumar
Dhruv Kumar
CKChristopher Kandl
Christopher Kandl
CHChase D’aRcy Hamilton
Chase D’aRcy Hamilton
YSYelizaveta Shnayder
Yelizaveta Shnayder
TTTerance Ted Tsue
Terance Ted Tsue
STSufi Mary Thomas
Sufi Mary Thomas
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with approximately 40 000 new cases per year in the United States and 500 000 worldwide.1 HNSCC arises from the epithelial lining of the upper aerodigestive tract, and the 5-year mortality rate from this disease is still close to 50%.2 Historically, surgery and radiation have been the mainstays of treatment. Traditionally, the role of chemotherapy has been enhancing the effects of radiation therapy. There are only 6 US Food and Drug Administration–approved drugs for the treatment of HNSCC, and only 2 that have been approved since 1978. However, the survival rates continue to be very low, highlighting the need for improved therapeutic approaches.

1 July 2010 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
KKKiran Kakarala
Kiran Kakarala
NBNeil Bhattacharyya
Neil Bhattacharyya

1 June 2023 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
TSTuleen Sawaf
Tuleen Sawaf
CVCelina G. Virgen
Celina G. Virgen
BRBryan Renslo
Bryan Renslo
NFNathan Farrokhian
Nathan Farrokhian
KYKatherine M. Yu
Katherine M. Yu
KSKevin J. Sykes
Kevin J. Sykes
Importance: Timely initiation of postoperative radiation therapy (PORT) is associated with reduced recurrence rates and improved overall survival in patients with head and neck squamous cell carcinoma (HNSCC). Measurement of the association of social-ecological variables with PORT delays is lacking.Objective: To assess individual and community-level factors associated with PORT delay among patients with HNSCC.Design, Setting, and Participants: This prospective cohort study carried out between September 2018 and June 2022 included adults with untreated HNSCC who were enrolled in a prospective registry at a single academic tertiary medical center. Demographic information and validated self-reported measures of health literacy were obtained at baseline visits. Clinical data were recorded, and participant addresses were used to calculate the area deprivation index (ADI), a measure of community-level social vulnerability. Participants receiving primary surgery and PORT were analyzed. Univariable and multivariable regression analysis was performed to identify risk factors for PORT delays.Exposures: Surgical treatment and PORT.Main Outcomes and Measures: The primary outcome was PORT initiation delay (>42 days from surgery). Risk of PORT initiation delay was evaluated using individual-level (demographic, health literacy, and clinical data) and community-level information (ADI and rural-urban continuum codes).Results: Of 171 patients, 104 patients (60.8%) had PORT delays. Mean (SD) age of participants was 61.0 (11.2) years, 161 were White (94.2%), and 105 were men (61.4%). Insurance was employer-based or public among 65 (38.5%) and 75 (44.4%) participants, respectively. Mean (SD) ADI (national percentile) was 60.2 (24.4), and 71 (41.8%) resided in rural communities. Tumor sites were most commonly oral cavity (123 [71.9%]), with 108 (63.5%) classified as stage 4 at presentation. On multivariable analysis, a model incorporating individual-level factors with health literacy in addition to community-level factors was most predictive of PORT delay (AOC= 0.78; R2, 0.18).Conclusions and Relevance: This cohort study provides a more comprehensive assessment of predictors of PORT delays that include health literacy and community-level measures. Predictive models that incorporate multilevel measures outperform models with individual-level factors alone and may guide precise interventions to decrease PORT delay for at-risk patients with HNSCC.